Pre-surgical targeted molecular therapy in renal cell carcinoma

Vitaly Margulis, Christopher G. Wood

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Pre-surgical systemic therapy with targeted molecular agents is an attractive option as an approach to the treatment of patients with renal cell carcinoma. This treatment strategy offers a rational approach for selecting patients with metastatic disease who are most likely to benefit from cytoreductive nephrectomy, but also allows access to treated tumour tissue to study the molecular mechanisms of response and resistance. In patients with locally advanced disease, this strategy offers the potential for improved resectability and timely delivery of systemic therapy to treat subclinical metastatic disease. Preliminary evidence indicates that the use of targeted therapies before nephrectomy is safe. Reliable therapy-specific prognostic biomarkers are needed for the optimal integration of aggressive surgical intervention and systemic therapy to maximize the oncological benefits for the patient.

Original languageEnglish (US)
Pages (from-to)150-153
Number of pages4
JournalBJU International
Volume103
Issue number2
DOIs
StatePublished - Jan 2009

Fingerprint

Molecular Targeted Therapy
Renal Cell Carcinoma
Nephrectomy
Therapeutics
Biomarkers

Keywords

  • Prognostic factors
  • Renal cell carcinoma
  • Targeted molecular therapy

ASJC Scopus subject areas

  • Urology

Cite this

Pre-surgical targeted molecular therapy in renal cell carcinoma. / Margulis, Vitaly; Wood, Christopher G.

In: BJU International, Vol. 103, No. 2, 01.2009, p. 150-153.

Research output: Contribution to journalArticle

Margulis, Vitaly ; Wood, Christopher G. / Pre-surgical targeted molecular therapy in renal cell carcinoma. In: BJU International. 2009 ; Vol. 103, No. 2. pp. 150-153.
@article{4ea1f55515e14454a4b7abe8f78ac997,
title = "Pre-surgical targeted molecular therapy in renal cell carcinoma",
abstract = "Pre-surgical systemic therapy with targeted molecular agents is an attractive option as an approach to the treatment of patients with renal cell carcinoma. This treatment strategy offers a rational approach for selecting patients with metastatic disease who are most likely to benefit from cytoreductive nephrectomy, but also allows access to treated tumour tissue to study the molecular mechanisms of response and resistance. In patients with locally advanced disease, this strategy offers the potential for improved resectability and timely delivery of systemic therapy to treat subclinical metastatic disease. Preliminary evidence indicates that the use of targeted therapies before nephrectomy is safe. Reliable therapy-specific prognostic biomarkers are needed for the optimal integration of aggressive surgical intervention and systemic therapy to maximize the oncological benefits for the patient.",
keywords = "Prognostic factors, Renal cell carcinoma, Targeted molecular therapy",
author = "Vitaly Margulis and Wood, {Christopher G.}",
year = "2009",
month = "1",
doi = "10.1111/j.1464-410X.2008.08095.x",
language = "English (US)",
volume = "103",
pages = "150--153",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Pre-surgical targeted molecular therapy in renal cell carcinoma

AU - Margulis, Vitaly

AU - Wood, Christopher G.

PY - 2009/1

Y1 - 2009/1

N2 - Pre-surgical systemic therapy with targeted molecular agents is an attractive option as an approach to the treatment of patients with renal cell carcinoma. This treatment strategy offers a rational approach for selecting patients with metastatic disease who are most likely to benefit from cytoreductive nephrectomy, but also allows access to treated tumour tissue to study the molecular mechanisms of response and resistance. In patients with locally advanced disease, this strategy offers the potential for improved resectability and timely delivery of systemic therapy to treat subclinical metastatic disease. Preliminary evidence indicates that the use of targeted therapies before nephrectomy is safe. Reliable therapy-specific prognostic biomarkers are needed for the optimal integration of aggressive surgical intervention and systemic therapy to maximize the oncological benefits for the patient.

AB - Pre-surgical systemic therapy with targeted molecular agents is an attractive option as an approach to the treatment of patients with renal cell carcinoma. This treatment strategy offers a rational approach for selecting patients with metastatic disease who are most likely to benefit from cytoreductive nephrectomy, but also allows access to treated tumour tissue to study the molecular mechanisms of response and resistance. In patients with locally advanced disease, this strategy offers the potential for improved resectability and timely delivery of systemic therapy to treat subclinical metastatic disease. Preliminary evidence indicates that the use of targeted therapies before nephrectomy is safe. Reliable therapy-specific prognostic biomarkers are needed for the optimal integration of aggressive surgical intervention and systemic therapy to maximize the oncological benefits for the patient.

KW - Prognostic factors

KW - Renal cell carcinoma

KW - Targeted molecular therapy

UR - http://www.scopus.com/inward/record.url?scp=58149145722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149145722&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2008.08095.x

DO - 10.1111/j.1464-410X.2008.08095.x

M3 - Article

C2 - 19007359

AN - SCOPUS:58149145722

VL - 103

SP - 150

EP - 153

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2

ER -